RxDoctor Payments Data

Lisa Chan, MD

Internal Medicine · Cypress, TXNPI 1992860829

Payments from drug & device makers

$11,044in general payments, 2019–2025

Across 662 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Amgen$883
  • Bayer$699
  • Boehringer Ingelheim$634
  • Pfizer$581
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$11,007100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,044 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,591
Medicare patients
184
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol52$61,463
OzempicSemaglutide48$61,014
VascepaIcosapent Ethyl58$45,452
JardianceEmpagliflozin25$39,447
MounjaroTirzepatide26$38,092
TymlosAbaloparatide14$36,284
ProliaDenosumab17$29,495
Tresiba Flextouch U-100Insulin Degludec32$21,684
TrulicityDulaglutide11$18,577
MyrbetriqMirabegron11$12,554
EliquisApixaban12$11,221
Icosapent Ethyl12$5,549
Rosuvastatin Calcium271$3,024
SymbicortBudesonide/Formoterol Fumarate14$2,950
Metoprolol Succinate161$2,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,364$64,41366 claims
Novo NordiskOzempic$2,010$61,01448 claims
Lilly USA, LLCMounjaro, Trulicity$380$56,66837 claims
Boehringer IngelheimJardiance$634$39,44725 claims
Radius Health, Inc.Tymlos$369$36,28414 claims
AmgenProlia$883$29,49517 claims
Astellas Pharma US IncMyrbetriq$385$12,55411 claims
PfizerEliquis$581$11,22112 claims
AbbVieSynthroid$437$57811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →